Abstract | BACKGROUND: AIM: DESIGN: An international, prospective, consecutive cohort post-marketing/phase IV/pharmacovigilance/quality improvement study of palliative care patients with neuropathic pain where the treating clinician had already made the decision to use a tricyclic antidepressant. Data were entered at set times: baseline, and days 7 and 14. Likert scales graded benefits and harms. SETTING/PARTICIPANTS: Twenty-one sites (inpatient, outpatient, community) participated in six countries between June 2016 and March 2019. Patients had clinician-diagnosed neuropathic pain. RESULTS: CONCLUSIONS: Benefits favoured amitriptyline while harms were similar for both medications.
|
Authors | Akram Hussein, Madeline Digges, Sungwon Chang, Jane Hunt, Matt Doogue, Debra Rowett, Meera Agar, Aynharan Sinnarajah, Danielle Kain, Simon Allan, Jason W Boland, David C Currow |
Journal | Palliative medicine
(Palliat Med)
Vol. 36
Issue 6
Pg. 938-944
(06 2022)
ISSN: 1477-030X [Electronic] England |
PMID | 35403513
(Publication Type: Clinical Trial, Phase IV, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents, Tricyclic
- Amitriptyline
- Nortriptyline
|
Topics |
- Aged
- Amitriptyline
(therapeutic use)
- Antidepressive Agents, Tricyclic
(therapeutic use)
- Hospices
- Humans
- Neuralgia
(drug therapy, etiology)
- Nortriptyline
(therapeutic use)
- Palliative Care
- Pharmacovigilance
- Prospective Studies
|